Zydus clarifies Delhi HC order restricting cancer drug Ikra supply - says not material

Litigation LossRegulatory & Legal View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹1133.80

prior close

₹1145.10

announcement price

After-mkt

timing

Nifty 100market+0.2%+2.2% vs market

Pharmaceuticals peers, median of 165sector+0.0%+2.4% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty 100 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.8

15m

-0.6

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+0.2+2.2+0.0+2.4

Next day

+1.5+0.1+1.4+0.0+1.5

+0.9+1.0-0.1-1.1+2.0

+1.3+0.8+0.5-0.5+1.8

+1.1+0.7+0.4-0.4+1.4

-0.8-0.1-0.7-1.7+0.9

-2.1-1.0-1.1-2.6+0.5

15d

-1.1+2.6-3.7-1.2+0.1

-0.2+1.5-1.7-0.5+0.3

-3.1-3.6+0.5-0.3-2.8

+0.6-4.4+5.0-2.3+2.9

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Delhi High Court has temporarily restricted Zydus Lifesciences from supplying its cancer drug Ikra in a patent dispute with AbbVie. In response to an NSE query, the company clarified that this court order is not material under SEBI listing rules or its own materiality policy. Zydus noted no unusual movement in its share price on July 14 and believes there is no material impact on the business.

Likely market impact

Temporary supply curb on one cancer drug due to patent dispute; company downplays material impact on business or shares.